AtriCure Announces Commitment to Improve Lives of 250,000 Atrial Fibrillation Patients

  AtriCure Announces Commitment to Improve Lives of 250,000 Atrial
  Fibrillation Patients

  Investment in Clinical Studies, Education to Advance New Technology Brings
                     Hope to Patients Suffering from Afib

Business Wire

WEST CHESTER, Ohio -- September 18, 2013

AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (Afib) solutions
partner, has announced a significant multi-year strategic investment in
clinical trial and educational initiatives aimed at reducing the global Afib
epidemic. The announcement coincides with Atrial Fibrillation Awareness Month,
which was created to bring attention to this growing public health issue. Afib
is associated with significant morbidity and mortality from stroke and heart
failure, as well as impaired quality of life.

"This year, we reassert our aggressive efforts to collaborate with leading
electrophysiologists, cardiologists, and surgeons to find long-lasting,
evidenced-based solutions that are proven through rigorous clinical trials,”
said Michael Carrel, president and CEO of AtriCure. “One in four Americans
aged 40 or older will be diagnosed with Afib in their lifetime. Without an
urgent focus on raising awareness and delivering effective and durable Afib
solutions, the physical and emotional impact on families, and the financial
impact on society, will be enormous. Our goal is to favorably impact the lives
of 250,000 patients and their family members by the end of the decade through
greater awareness and treatment.”

To accomplish this goal AtriCure is making significant investments in clinical
science and physician education initiatives. The ABLATE PAS study is the
largest and most rigorous multi-centered surgical ablation study ever
attempted. It will build upon the success demonstrated in AtriCure’s landmark
FDA trial and further support the durability of the Synergy Ablation System
for the treatment of persistent and long-standing persistent Afib. AtriCure’s
Synergy Ablation System is currently the only FDA-approved surgical device for
the treatment of Afib. As of this month, the ABLATE PAS study passed the
halfway point in patient enrollment and will continue to follow patients for
three years post procedure. Additionally, in an effort to ensure
standardization of the Maze IV procedure to achieve the highest possible
quality outcomes, AtriCure has provided in-depth surgeon education to over
1,000 surgeons.

In recognition that patient awareness is a key aspect of making an impact on
this healthcare epidemic, AtriCure has developed a new campaign focused on
Afib risk awareness and treatment options entitled, “ACT Against Afib”. “ACT”
is an acronym for the three steps involved in patient awareness and
understanding treatment options: Assess your risk, Consult with your doctor,
and Treat your Afib. The campaign will include advertising, press releases to
the public, a website for patients and physicians, media kits for hospitals
and advocacy groups to partner on the campaign and special events throughout
the year.

“As a leader in the clinical research and treatment of Afib, we’re
all-too-familiar with its devastating effects, and the near epidemic levels of
people suffering from Afib. Our goal is to partner with physicians to provide
superior treatment options as well as to create greater public awareness about
this progressive disease and the options available,” according to Sydney
Gaynor, MD, cardiothoracic surgeon and medical director at AtriCure. Further,
“The ACT Against Afib campaign is an excellent way to spread the word about
the risks and treatment options, and we encourage physicians to become
involved through the ACT campaign.”

About AtriCure, Inc.

AtriCure, Inc. is a leading atrial fibrillation solutions partner, providing
innovative products, professional education and support for clinical science
to reduce the economic and social burden of atrial fibrillation. AtriCure's
Synergy Ablation System is the first and only device approved by the Food and
Drug Administration (FDA) for the surgical treatment of Persistent and
Longstanding Persistent forms of Afib in patients undergoing certain open
heart procedures concomitantly (simultaneously). AtriCure's AtriClip™ Left
Atrial Appendage (LAA) occlusion device is the most widely implanted device
for LAA management worldwide.Afib affects more than two million people
worldwide and is estimated to cost more than $6.5 billion annually in
healthcare expenses. The number affected by Afib is expected to grow to 12
million by 2050.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments
that AtriCure expects, believes or anticipates will or may occur in the
future, such as earnings estimates, other predictions of financial
performance, launches by AtriCure of new products and market acceptance of
AtriCure’s products. Forward-looking statements are based on AtriCure’s
experience and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many of
which are beyond AtriCure’s control. These risks and uncertainties include the
rate and degree of market acceptance of AtriCure’s products, AtriCure’s
ability to develop and market new and enhanced products, the timing of and
ability to obtain and maintain regulatory clearances and approvals for its
products, the timing of and ability to obtain reimbursement of procedures
utilizing AtriCure’s products, competition from existing and new products and
procedures or AtriCure’s ability to effectively react to other risks and
uncertainties described from time to time in AtriCure’s SEC filings, such as
fluctuation of quarterly financial results, reliance on third party
manufacturers and suppliers, litigation or other proceedings, government
regulation and stock price volatility. AtriCure does not guarantee any
forward-looking statement, and actual results may differ materially from those
projected. AtriCure undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.

Contact:

Rasor Marketing Communications
Becky Fickenworth, 513-793-1234
becky@rasormarketing.com
 
Press spacebar to pause and continue. Press esc to stop.